|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||3.90 / 11.90|
LEXINGTON, Mass., June 25, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc.
LEXINGTON, Mass., June 20, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc.
Data Demonstrate Statistically and Clinically Significant Activity of Topical Ocular 0.1% Reproxalap Across a Broad Array of Signs and Symptoms
Insiders are taking advantage of opportunities in Intra-Cellular Therapies and Aldeyra.
The Lexington, Mass.-based company unveiled results from its Phase 2a study of ADX-102 in dry eye disease. Other biotech movers in premarket trading on Sept. 12 include Sage Therapeutics and Intercept Pharmaceuticals.
Presentation to Include Additional Data From Aldeyra's Recently Completed Phase IIa Clinical Trial of NS2 in Allergic Conjunctivitis
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.